Clinical Trials Browser

Phase 2 × OTHER × Neoplasms, Second Primary × Clear all

Smoking Cessation, Neoplasms, Second Primary, Behavior, Addictive

NCT05217069 2025-04-16

FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC

Phase 2 Completed

57 enrolled

Tumor-Agnostic

Neoplasms, Second Primary

NCT05855811 2024-07-15

PREDOSTAR

Phase 2 Recruiting

400 enrolled

Neoplasms, Recurrence, Neoplasms, Second Primary

NCT02530515 2019-10-29

Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia

Phase 2 Completed

8 enrolled 6 charts

Classical hematologyLymphoidOther hematologic neoplasm

Lymphadenopathy, Anemia, Communicable Diseases, Fever, Lymphocytosis, Thrombocytopenia, Weight Loss, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Neoplasms, Second Primary

NCT04034173 2019-07-26

Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation

Phase 2 Not yet recruiting

120 enrolled

Gastrointestinal

Colorectal Neoplasms, Neoplasms, Second Primary

NCT00400426 2013-06-19

DAHANCA 20 Palliative Radiotherapy for Head and Neck Cancer

Phase 2 Completed

100 enrolled

Head & Neck

Head and Neck Neoplasms, Recurrence, Neoplasms, Second Primary

Clinical Trials

TTOP

FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC

PREDOSTAR

Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia

Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation

DAHANCA 20 Palliative Radiotherapy for Head and Neck Cancer